Zobrazeno 1 - 10
of 55
pro vyhledávání: '"Can-ming Chen"'
Publikováno v:
Communications Chemistry, Vol 6, Iss 1, Pp 1-7 (2023)
Abstract One-carbon homologation reactions based on one-carbon insertion into the N−O bond of heterocycles have received tremendous interest over the past decades. However, these protocols have to rely on the use of hazardous and not easily accessi
Externí odkaz:
https://doaj.org/article/465c741860f1472589e0e776c817d1d2
Autor:
Hang-Hao Li, Ya-Nan Meng, Can-Ming Chen, Yu-Qi Wang, Zhi-Xin Zhang, Zhou Xu, Bo Zhou, Long-Wu Ye
Publikováno v:
Science China Chemistry. 66:1467-1473
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::edf00335e7b5b5dcf82a999e889bf71a
https://doi.org/10.1007/s11426-022-1536-9
https://doi.org/10.1007/s11426-022-1536-9
Publikováno v:
Organic Chemistry Frontiers. 10:203-208
An efficient copper-catalyzed formal [4 + 1] annulation of N-propargyl ynamides with diketones has been developed, allowing practical and atom-economic synthesis of valuable pyrrole-substituted dioxoles in generally moderate to excellent yields.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b87f069d98d2bd13bbdbd1f3efe3cd06
https://doi.org/10.1039/d2qo01786e
https://doi.org/10.1039/d2qo01786e
Publikováno v:
Angewandte Chemie. 135
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9538751556688b3c99f847c413dc84a9
https://doi.org/10.1002/ange.202303670
https://doi.org/10.1002/ange.202303670
Autor:
Zhi-Ming Shao, Zhong-Hua Wang, Wen-Tao Yang, Jian-Jun Zou, Xiao-Yu Zhu, Yanhui Xu, Xizi Chen, Xiaomao Guo, Wen-Jun Chai, Xiang-Jie Sun, Ying Xu, Xiao-Yan Ma, Shen Zhao, Xin Hu, A-Yong Cao, Xiao-Yan Huang, Can-Ming Chen, Zhen Hu, Yi-Feng Hou, Jun-Jie Li, Lei Fan, Ke-Da Yu, Guang-Yu Liu, Gen-Hong Di, Jiong Wu, Song-Yang Wu, Yi-Zhou Jiang, Li Chen
Supplementary Data from Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0cf9dd20e1c2e70c6f874ea9cfec3cb9
https://doi.org/10.1158/1078-0432.22487412.v1
https://doi.org/10.1158/1078-0432.22487412.v1
Autor:
Zhi-Ming Shao, Zhong-Hua Wang, Wen-Tao Yang, Jian-Jun Zou, Xiao-Yu Zhu, Yanhui Xu, Xizi Chen, Xiaomao Guo, Wen-Jun Chai, Xiang-Jie Sun, Ying Xu, Xiao-Yan Ma, Shen Zhao, Xin Hu, A-Yong Cao, Xiao-Yan Huang, Can-Ming Chen, Zhen Hu, Yi-Feng Hou, Jun-Jie Li, Lei Fan, Ke-Da Yu, Guang-Yu Liu, Gen-Hong Di, Jiong Wu, Song-Yang Wu, Yi-Zhou Jiang, Li Chen
Supplementary Table from Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f5866ab4f3e90784a490b8e46ab2dcc
https://doi.org/10.1158/1078-0432.22487397.v1
https://doi.org/10.1158/1078-0432.22487397.v1
Autor:
Zhi-Ming Shao, Zhong-Hua Wang, Wen-Tao Yang, Jian-Jun Zou, Xiao-Yu Zhu, Yanhui Xu, Xizi Chen, Xiaomao Guo, Wen-Jun Chai, Xiang-Jie Sun, Ying Xu, Xiao-Yan Ma, Shen Zhao, Xin Hu, A-Yong Cao, Xiao-Yan Huang, Can-Ming Chen, Zhen Hu, Yi-Feng Hou, Jun-Jie Li, Lei Fan, Ke-Da Yu, Guang-Yu Liu, Gen-Hong Di, Jiong Wu, Song-Yang Wu, Yi-Zhou Jiang, Li Chen
Supplementary Figure from Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2309b0f1682e17911f052505f61db101
https://doi.org/10.1158/1078-0432.22487400.v1
https://doi.org/10.1158/1078-0432.22487400.v1
Autor:
Zhi-Ming Shao, Zhong-Hua Wang, Wen-Tao Yang, Jian-Jun Zou, Xiao-Yu Zhu, Yanhui Xu, Xizi Chen, Xiaomao Guo, Wen-Jun Chai, Xiang-Jie Sun, Ying Xu, Xiao-Yan Ma, Shen Zhao, Xin Hu, A-Yong Cao, Xiao-Yan Huang, Can-Ming Chen, Zhen Hu, Yi-Feng Hou, Jun-Jie Li, Lei Fan, Ke-Da Yu, Guang-Yu Liu, Gen-Hong Di, Jiong Wu, Song-Yang Wu, Yi-Zhou Jiang, Li Chen
Purpose:Camrelizumab, an mAb against programmed cell death protein 1 (PD-1), plus nab-paclitaxel exhibited promising antitumor activity in refractory metastatic immunomodulatory triple-negative breast cancer (TNBC). Famitinib is a tyrosine kinase inh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0933947e0d4bbbf77ca8537a0f12d16e
https://doi.org/10.1158/1078-0432.c.6532512.v1
https://doi.org/10.1158/1078-0432.c.6532512.v1
Publikováno v:
Angewandte Chemie. 135
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::754fd73222b7ac4ffff7581df4f48175
https://doi.org/10.1002/ange.202216923
https://doi.org/10.1002/ange.202216923
Autor:
Li Chen, Yi-Zhou Jiang, Song-Yang Wu, Jiong Wu, Gen-Hong Di, Guang-Yu Liu, Ke-Da Yu, Lei Fan, Jun-Jie Li, Yi-Feng Hou, Zhen Hu, Can-Ming Chen, Xiao-Yan Huang, A-Yong Cao, Xin Hu, Shen Zhao, Xiao-Yan Ma, Ying Xu, Xiang-Jie Sun, Wen-Jun Chai, Xiaomao Guo, Xizi Chen, Yanhui Xu, Xiao-Yu Zhu, Jian-Jun Zou, Wen-Tao Yang, Zhong-Hua Wang, Zhi-Ming Shao
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 28(13)
Purpose: Camrelizumab, an mAb against programmed cell death protein 1 (PD-1), plus nab-paclitaxel exhibited promising antitumor activity in refractory metastatic immunomodulatory triple-negative breast cancer (TNBC). Famitinib is a tyrosine kinase in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa377908e39a2737b651080926b36de7
https://pubmed.ncbi.nlm.nih.gov/35442426
https://pubmed.ncbi.nlm.nih.gov/35442426